Drug tranport(ers) and the diseased brain : proceedings of the Esteve Foundation Symposium 11, held between 6 and 9 October 2004, S'Agaró (Girona), Spain
著者
書誌事項
Drug tranport(ers) and the diseased brain : proceedings of the Esteve Foundation Symposium 11, held between 6 and 9 October 2004, S'Agaró (Girona), Spain
（International congress series, no. 1277）
Elsevier, c2005
- タイトル別名
-
Drug tranport
Drug tranporters and the diseased brain
大学図書館所蔵 件 / 全3件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and indexes
内容説明・目次
内容説明
There are many potent drugs available for many diseases of the brain (e.g. Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Stroke, Brain tumours). The effectiveness, however, is not optimal since barriers in the brain prevent the drugs from reaching the brain in sufficient therapeutic concentrations (e.g. the blood-brain barrier and the blood-cerebrospinal fluid barrier). "Drug Transport(ers) and the Diseased Brain" contains the papers of a timely symposium held in Spain between 6 and 9 October 2004, which sets out not only the point of view of the academic researcher and the clinician, but also from the pharmaceutical industrial on how to overcome these barriers and how to treat brain diseases effectively.
目次
About the Esteve Foundation. Disclaimer. Group photo. Introduction and Acknowledgements. List of participants. Preface. The conditions for considering drug transport/targeting to the brain. Physiology of the blood-brain barrier and its consequences for drug transport to the brain (N.J. Abbott). The blood-brain barrier and treatment of lysosomal storage diseases (J.M. Aerts et al.). The priorities/needs of the pharmaceutical industry in drug delivery to the brain (M. Lemaire, S. Desrayaud). Influx transporters and drug targeting. Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems (W.M. Pardridge). Carrier-mediated transport to enhance drug delivery to brain (Q.R. Smith). Influx transporters and drug targeting: Application of peptide and cation transporters (A. Tsuji). Application of nanoparticles for the delivery of drugs to the brain (J. Kreuter). Application, efficiency and cargo-dependence of transport peptides (J.P.M. Langedijk, T. Olijhoek, R.H. Meloen). Efflux transporters at BBB. Efflux transport systems at the blood-brain barrier and blood CSF barrier (H. Kusuhara, Y. Sugiyama). Experimental models to evaluate the role of P-glycoprotein in the blood-brain tumor barrier (O. van Tellingen, E.M. Kemper, T. Buckle). Overcoming MDR at the blood-brain barrier (G. Fricker). Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by RNA interference (H. Lage). The multidrug resistance protein BMDP/ABCG2: A new and highly relevant efflux pump at the blood-brain barrier (A. Drees et al.). Additional approaches for drug delivery/targeting to the BBB/brain. Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier (R. Gabathuler et al.). Diphtheria toxin receptor-targeted brain drug delivery (P.J. Gaillard, A. Brink, A.G. de Boer). The use of Pep: Trans vectors for the delivery of drugs into the central nervous system (J.-M. Scherrmann, J. Temsamani). Single domain antibodies as blood-brain barrier delivery vectors (A. Abulrob et al.). The BBB as a drug target from the clinical point of view. The blood-brain barrier in trauma, stroke and edema (J. Verlooy, J. Van Reempts). The blood-brain barrier in multiple sclerosis (S. McQuaid, J. Kirk). The blood-brain barrier in diabetes mellitus: A critical review of clinical and experimental findings (E. Tolia et al.). Final discussion (A.G. de Boer). Novel opportunities for the treatment of brain diseases (A.G. de Boer). Author index. Keyword index.
「Nielsen BookData」 より